Evidence map›Paper›PMID 22759323›Full record

Trial reportHelicobacter2012

Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate.

Marco Manfredi, Barbara Bizzarri, Gian Luigi de'Angelis

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Helicobacter, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02547012 (Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02547012 nacompletednot on this mapstarted 2013, after this paper: background citation

Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial

TypeinterventionalSponsorKaohsiung Veterans General Hospital.Ran2013 to 2017Enrolled51ConditionsHelicobacter Pylori InfectionArmsesomeprazole+amox+levo+tetra, esomeprazole+amox+levo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Rescue Therapies forAntibiotics (Basel, Switzerland) · 2021
    Article
  5. Optimization Strategies Aimed to Increase the Efficacy ofMolecules (Basel, Switzerland) · 2020
    Review
  6. First-line therapies forAnnals of gastroenterology · 2017
    Review
  7. Optimal First-Line Treatment forGastroenterology research and practice · 2016
    Review
  8. Review
  9. Review
  10. Review
  11. First- and second-lineAnnals of gastroenterology · 2014
    Article
  12. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori.World journal of gastrointestinal pharmacology and therapeutics · 2013
    Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Marco ManfrediGastroenterology Unit, Department of Medicine, Sant'Anna Hospital-AUSL of Reggio Emilia, Castelnovo ne' Monti, Italy. manfredim@ausl.re.it
Barbara Bizzarri
Gian Luigi de'Angelis
University of Parma · ITOspedale Sant'Anna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the eradication of H. pylori infection, even today, the main international guidelines recommend the triple therapy as first-line regimen, although its effectiveness is clearly decreasing. As second-line treatment, the bismuth-containing quadruple therapy is the most used regimen, although several other therapies are studied. The Italian guidelines recommend, alternatively, sequential therapy or triple therapy as first-line treatment and levofloxacin-containing triple therapy as second-line regimen. We wanted to assess the overall eradication rate of Helicobacter pylori infection in two therapeutic rounds following the Italian guidelines in clinical practice. MATERIALS AND

methodsWe treated 231 consecutive Helicobacter pylori-positive patients by sequential therapy and we verified the eradication 8-10 weeks after treatment by stool antigen test. Patients positive for stool antigen test received levofloxacin-containing triple therapy, as second-line therapy, according to Italian Guidelines and they were again submitted to the fecal test 8-10 weeks after the end of treatment.

resultsIn the first-line regimen, we obtained an eradication rate of 92.6%, in the second-line of 75.0% and as cumulative result we achieved a 97.8% of eradication, in per-protocol analysis.

conclusionsSequential therapy as first-line and levofloxacin-containing triple therapy as second-line represent a good combination to eradicate Helicobacter pylori infection in only two rounds.

Indexed as

LevofloxacinAdolescentAdultAgedAged, 80 and overAmoxicillinAnti-Bacterial AgentsDrug Therapy, CombinationFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMiddle AgedOfloxacinOmeprazoleAmoxicillinAnti-Bacterial AgentsLevofloxacinOfloxacinOmeprazole

Identifiers

PMID22759323
OpenAlexW1952956048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.